“If successful and approved, this would more than double the addressable population versus the currently approved indication.”

In context

“nce for a subcutaneous PDL1 because it can be used in their practices and eliminates the need to refer their patients to infusion centers. We also anticipate meaningful readouts this year for POTS and LRx. PADCER plus pembrolizumab is the most prescribed first-line treatment for locally advanced metastatic urothelial cancer in the US. We are working to more than double the total addressable patient population in the US for parts with potentially registrational interim data we expect this year from ongoing pivotal studies in muscle-invasive bladder outcomes. We are also working to reach a significantly expanded population of patients with multiple myeloma. We are anticipating a phase two readout this year for LRxview in a study for double-class exposed relapsed refractory multiple myeloma. If successful and approved, this would more than double the addressable population versus the currently approved indication. In addition to the increased addressable population, moving to earlier lines of therapy is expected to increase the duration of treatment and potentially create an inflection point in infectious growth. We expect to begin pivotal studies for our ADC later this year. This will be for first-line metastatic head and neck squamous cell carcinoma and second-line non-small cell lung cancer. We also anticipate a first-line pivotal study start for SV Sigmata top with doctor. This is a novel integrin beta six targeting VADOPIN ADC, but if successful and approved, has the opportunity to change the standard of care globally for IBC Express in human. Both these ADCs, PDL1V, and SVB are potential first-in-class ADCs using payload that elicits immunogenic cell death. And in combination with any new che”